人附睾蛋白4在妇科疾病伴肾功能损害患者诊疗中的应用被引量：2

Clinical application of human epididymis protein 4 in gynecological diseases with renal damage patients

导出

摘要目的探讨利用人附睾蛋白4(human epididymis protein 4,HE4)诊断妇科疾病和监测疗效时,如何减少肾功能损害对HE4水平的影响。方法比较各疾病组和对照组血清HE4、CA125水平。分析血清HE4与尿素、肌酐、尿酸和胱抑素C水平的相关性。结果良性+肾功能损害组血清HE4明显高于对照组、良性组和内膜癌组,差异有统计学意义(P<0.01),与卵巢癌组比较,差异无统计学意义(P>0.05)。良性+肾功能损害组、良性组、内膜癌组血清CA125比较差异无统计学意义(P>0.05)。血清HE4与尿素、肌酐、胱抑素C水平呈正相关(P<0.05),与尿酸水平无相关性(P>0.05)。卵巢癌+肾功能损害组、内膜癌+肾功能损害组血清HE4水平明显高于卵巢癌组、内膜癌组,差异有统计学意义(P<0.05)。结论血清尿素、肌酐和胱抑素C结果有助于排除肾功能损害导致的血清HE4水平增高。应注意高HE4伴肾功能损害患者的肿瘤性质分析,避免对妇科恶性肿瘤伴肾功能损害患者病情估计过重。 Objective To explore how to decrease renal damage effects on serum HE4 values when diagnosing gynaecological diseases and monitoring curative effect. Methods Serum HE4 and cancer antigen 125 concentrations of all disease groups and control group were compared. The correlation between serum HE4 and Urea,CRE,Cys C values was analyzed. Results Serum HE4 values in gynecological benign diseases with renal damage group significantly increased compared with the benign gynecological diseases,endometrial adenocarcinoma and normal control groups,with the differences statistically significant（ P〈0. 01）. And the differences were not statistically significant,compared with ovarian carcinoma group（ P〈0. 05）. Serum CA125 values in the gynecological benign diseases with renal damage group,benign gynecological diseases group and endometrial adenocarcinoma group were different,and the differences were not statistically significant,（ P〈0. 05）. The serum HE4 values were positively correlated to the serum values of Urea,CRE and Cys C（ P〈0. 05）,but not correlated to the UA（ P〈0. 05）. Serum HE4 values in ovarian carcinoma with renal damage and endometrial adenocarcinoma with renal damage groups significantly increased compared with the ovarian carcinoma and endometrial adenocarcinoma groups,and the differences were not statistically significant,（ P〈0. 05）. Conclusion Serum Urea,CRE and Cys C values help to eliminate high serum HE4 caused by renal damage. Tumor nature in renal damaged patients with high serum HE4 should be paid attention to avoid overestimating the illness of gynecology malignant tumor patients with renal damage.

作者张蓉陈娟慕莹张美莲

机构地区青岛市中心医院检验科

出处《中国卫生检验杂志》 CAS 2017年第14期2044-2046,共3页 Chinese Journal of Health Laboratory Technology

关键词人附睾蛋白4 妇科疾病肾功能损害 Human epididymis protein 4 Gynecological disease Renal damage

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献5

1江丽霞,朱亚飞,何华,李峰,胡蓉,汤显湖.肾功能对血清HE4水平及ROMA指数的影响研究[J].中国卫生检验杂志,2015,25(14):2333-2335. 被引量：3
2吕艳文,杨力,张玫,姜丽红,牛锦华,侯军,崔秀红.妇科良性疾病并慢性肾功能不全患者人附睾蛋白4水平变化及意义[J].中华实用诊断与治疗杂志,2015,29(4):415-416. 被引量：4
3徐春琳,杨艳华,王惠兰,左宏玲,王英,路晓琳.血清人附睾蛋白4对卵巢上皮性癌的诊断价值[J].中国实用妇科与产科杂志,2010,26(9):684-686. 被引量：17
4马潇潇,任瑞锋,张建杰,边英新,李俊,管燕.慢性肾脏疾病患者人附睾蛋白4水平变化[J].河北医药,2015,37(7):1019-1021. 被引量：3
5凡瞿明,卢小岚,王强,汪光蓉,王东生,蔡艳娟,程吉兵.人附睾蛋白4评价慢性肾脏病患者肾功能的价值[J].临床检验杂志,2016,34(1):38-39. 被引量：6

二级参考文献57

1Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HFA expression in normal and malignant human tissues [J]. Mod Pathol, 2006, 19: 847-853.
2Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HFA ( WFD- C2 ) protein is a biomarker for ovarian carcinoma [ J ]. Cancer Res, 2003, 63: 3695-3700.
3Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HFA- (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms[J]. Oncogene, 2002, 21 (17) : 2768-2773.
4Drapkin R, Horsten HH, Lin Y, et al. Human epididymis protein 4 (HFA) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas [ J ]. Cancer Res, 2005, 65 : 2162-2169.
5Osman N, O 'Leary N, Mulcahy E, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre[J]. Ir Med J, 2008, 101(8) : 245 -247.
6Obermair A, Fuller A, Lopez-Varela E, et al. A new progn- ostic model for FIGO stage 1 epithelial ovarian cancer[ J]. Gynecol Oncol, 2007, 104(3): 607-611.
7Moore RG, Mc Meekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HFA and CA125 for the prediction of ovarian cancer in patients with a pelvic mass[ J]. Gynecol Oneol, 2009, 112(1) : 40-46.
8Seholler N, Crawford M, Sato A. Bead-based ELISA for validation of ovarian cancer early detection markers [ J ]. Clin Cancer Res, 2006, 12(7 Pt 1): 2117-2124.
9Seibaek L, Petemen LK, Blaakaer J, et al. Symptom interpretation and health care seeking in ovarian cancer. BMC Womens Health, 2011,11 : 31.
10Bamias A, Karadimou A, Soupos N, et al. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy:a single institution experience. Gynecol Onco1,2011,123: 37-42.